Neuronetics's Total Assets for the quarter that ended in Mar. 2026 was €108.5 Mil.
During the past 12 months, Neuronetics's average Total Assets Growth Rate was -7.90% per year.
During the past 3 years, the average Total Assets Growth Rate was 36.00% per year.
During the past 5 years, the average Total Assets Growth Rate was 33.90% per year.
During the past 10 years, Neuronetics's highest 3-Year average Total Assets Growth Rate was 53.40%. The lowest was 24.00%. And the median was 39.60%.
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Neuronetics's Asset Turnover for the quarter that ended in Mar. 2026 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Neuronetics Total Assets Related Terms
Neuronetics Total Assets Historical Data
* Premium members only.
The historical data trend for Neuronetics's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Neuronetics's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neuronetics (FRA:NRC) has a Total Assets of €108.5 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Neuronetics and its competitors.
Is Neuronetics' Total Assets too high?
Neuronetics' current Total Assets is €108.5 Mil. Overall, Neuronetics has a GF Score™ of 57/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Neuronetics' Total Assets compare to ZOMDF and OM?
Neuronetics' Total Assets of €108.5 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Medical Devices & Instruments company?
A good Total Assets depends on the Medical Devices & Instruments industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Neuronetics and its competitors. Neuronetics's current Total Assets is €108.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neuronetics stock overvalued right now?
Based on GuruFocus' analysis, Neuronetics (FRA:NRC) is currently considered Modestly Undervalued. The stock's GF Value™ is €1.53, compared to a current price of €1.21 — trading 20.9% below its estimated fair value. The current Total Assets is €108.5 Mil. Neuronetics' overall GF Score™ is 57/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Neuronetics (FRA:NRC), the current Total Assets is €108.5 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Neuronetics (FRA:NRC) Overvalued in 2026?
Based on GuruFocus' analysis, Neuronetics stock appears to be undervalued.
The current stock price of €1.21 is trading 20.9% below its estimated GF Value™ of €1.53.
GuruFocus considers Neuronetics to be Modestly Undervalued.
Key valuation signals for FRA:NRC:
Total Assets: €108.5 Mil
GF Value™: €1.53 vs. price of €1.21 (20.9% below fair value)
No single metric tells the full story. See the FRA:NRC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Neuronetics Inc a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advance Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advance Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address the existing treatment options. The company operates in two segments: medical devices and clinic services.
57GF Score
Get the complete analysis for FRA:NRC
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:NRC has been successfully added to your 
